TransCode Therapeutics Inc. (NASDAQ:RNAZ) Short Interest Update

by · The Cerbat Gem

TransCode Therapeutics Inc. (NASDAQ:RNAZ – Get Free Report) was the target of a significant growth in short interest during the month of June. As of June 15th, there was short interest totaling 56,527 shares, a growth of 100.9% from the May 31st total of 28,142 shares. Based on an average daily volume of 230,735 shares, the short-interest ratio is presently 0.2 days. Currently, 6.0% of the company’s stock are sold short.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of TransCode Therapeutics in a report on Tuesday, April 21st. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, TransCode Therapeutics currently has a consensus rating of “Sell”.

Check Out Our Latest Stock Report on RNAZ

TransCode Therapeutics Stock Up 18.5%

Shares of NASDAQ:RNAZ traded up $0.97 during trading on Tuesday, hitting $6.21. 51,317 shares of the company traded hands, compared to its average volume of 152,712. The business’s fifty day moving average is $6.34 and its 200-day moving average is $8.05. The stock has a market capitalization of $5.90 million, a price-to-earnings ratio of -0.12 and a beta of 1.29. TransCode Therapeutics has a one year low of $3.82 and a one year high of $20.99.

TransCode Therapeutics (NASDAQ:RNAZ – Get Free Report) last released its quarterly earnings data on Friday, May 15th. The company reported ($21.28) earnings per share (EPS) for the quarter.

About TransCode Therapeutics

(Get Free Report)

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B.

Featured Articles